Bristol-Myers Squibb (BMS) agreed to a deal with Novo Nordisk to use its autoimmune disease research program. The agreement gives BMS access to Novo’s discovery biologics research program, which is focused on “modulating the innate immune system as a therapy for autoimmune disease,” according to The Wall Street Journal.

Terms of the agreement were not disclosed. BMS affirmed its “long-standing commitment to immunoscience.” The drugmaker currently markets Yervoy, an immunotherapy approved for use in advanced melanoma.